Story ContinuesPremium instrument placements reached over 5,200 units in the quarter, including approximately 1,600 IDEXX inVue Dx analyzers, on pace for our full year inVue Dx placement goal of 5,500 units. Our updated full year overall organic revenue growth outlook is 8.5% to 9.7%, and with organic CAG Diagnostics recurring revenue growth of 9.5% to 10.7%. Consumable revenue growth included benefits from net new customer gains in our premium instrument installed base and expanded testing utilization. Globally, we placed 1,602 IDEXX inVue Dx instruments in Q2 and over 1,000 new and competitive Catalyst instruments globally, with nearly 300 in the U.S. IDEXX Global Reference Lab revenues increased over 10% organically in Q2, led by volume gains. IDEXX (IDXX) Q2 2026 Earnings Call Transcript was originally published by The Motley Fool